A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results
- Cite this article as:
- Ribba, B., Marron, K., Agur, Z. et al. Bull. Math. Biol. (2005) 67: 79. doi:10.1016/j.bulm.2004.06.007
Doxorubicin treatment outcomes for non-Hodgkin’s lymphomas (NHL) are mathematically modelled and computationally analyzed. The NHL model includes a tumor structure incorporating mature and immature vessels, vascular structural adaptation and NHL cell-cycle kinetics in addition to Doxorubicin pharmacokinetics (PK) and pharmacodynamics (PD). Simulations provide qualitative estimations of the effect of Doxorubicin on high-grade (HG), intermediate-grade (IG) and low-grade (LG) NHL. Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system.